Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin ASilvana Mourón, Miguel Quintela-Fandiño, José Á. García-Sáenz et al.|Nature Communications|2022Cited by 14
Data from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0
Data from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Steven J. Isakoff, Julia Wulfkuhle et al.|Unknown|2023Cited by 0